Screening Cytotoxic Polypeptides by Suppressing Ribotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening molecular libraries comprising toxin-derived ribotoxic polypeptides are hindered by ribotoxic effects, leading to inefficient identification of cytotoxic chimeric proteins with desired properties, as existing approaches often require additional engineering steps and result in molecules with less than ideal properties due to unwanted selection biases and production inefficiencies.
Innovation Solution
The development of methods that reduce or eliminate ribotoxicity by using non-ribotoxic forms of toxin regions through mutations or performing screenings in the presence of inhibitors, allowing for the selection of cytotoxic proteins and polypeptides with improved target molecule binding affinity and cellular internalization capabilities within protein display systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If molecular libraries comprising ribotoxic polypeptides are screened using conventional methods, then cytotoxic chimeric proteins can be identified, but ribotoxic effects cause unwanted selection biases and production inefficiencies
Solution Approach 1:
The patent applies preliminary action by temporarily reducing or eliminating ribotoxicity through mutations or inhibitors during the screening process. This allows the screening to proceed without ribotoxic interference, and the ribotoxic capability is restored in the final cytotoxic molecule through site-specific reversion or removal of the inhibiting element
Solution Approach 2:
The patent uses an intermediary approach by introducing temporary mutations or inhibitors that mediate the screening process. These intermediaries reduce ribotoxicity during screening but are designed to be removable or reversible, allowing the final molecule to retain full cytotoxic functionality
2Reliability
If additional engineering steps are taken to overcome ribotoxicity issues, then cytotoxic molecules can be produced, but the process complexity and time increase
Solution Approach 1:
The patent reduces process complexity by performing preliminary reduction of ribotoxicity directly during screening rather than requiring separate engineering steps after screening. This integration eliminates multiple sequential steps and reduces overall process complexity
Solution Approach 2:
The patent applies parameter changes by temporarily modifying ribotoxicity parameters (through mutations or inhibitors) during screening, then restoring the original parameters in the final molecule. This parameter modulation approach simplifies the overall process compared to traditional multi-step engineering approaches
3Measurement precision
If screening is performed with full ribotoxicity active, then selection for desired characteristics is possible, but ribotoxic effects dominate the selection bias
Solution Approach 1:
The patent extracts the harmful ribotoxic effect from the screening process by temporarily reducing or eliminating it through mutations or inhibitors. This allows the screening to measure desired characteristics without the confounding influence of ribotoxicity-driven selection bias
Solution Approach 2:
The patent applies preliminary anti-action by introducing elements (mutations or inhibitors) that counteract ribotoxicity before screening begins. This preliminary counter-action prevents ribotoxic selection bias from dominating the screening results
Data Source
AI summary
The present invention relates to methods of screening libraries of chimeric molecules comprising ribotoxic polypeptides, where screening is based on the interim reduction or elimination of ribotoxicity and the methods can identify cytotoxic molecules, each comprising a binding region and a ribotoxic region which jointly possess a desired assay-selectable characteristic, such as, e.g., binding to a target biomolecule, binding to a target cell, and/or cellular internalization.